Shanghai - Delayed Quote CNY

Zhejiang Qianjiang Biochemical Co., Ltd (600796.SS)

5.65
-0.05
(-0.88%)
At close: May 23 at 3:00:03 PM GMT+8
Loading Chart for 600796.SS
  • Previous Close 5.70
  • Open 5.70
  • Bid 5.64 x --
  • Ask 5.65 x --
  • Day's Range 5.63 - 5.75
  • 52 Week Range 3.88 - 9.30
  • Volume 4,280,000
  • Avg. Volume 7,840,378
  • Market Cap (intraday) 4.896B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 29.74
  • EPS (TTM) 0.19
  • Earnings Date --
  • Forward Dividend & Yield 0.03 (0.55%)
  • Ex-Dividend Date Jun 27, 2024
  • 1y Target Est --

Zhejiang Qianjiang Biochemical Co., Ltd. develops, produces, and sells biopesticide and veterinary drugs, and biological medicine intermediates in China. The company provides biopesticide products comprising validamycin, gibberellic acid, abamectin, methylamino abamectin, and other products; biological drugs, including colistin sulfate premix and colistin sulphate; biological drugs intermediates; and feed additives. It also offers external heating services. The company exports its products to the United States, West Europe, South America, and Southeast Asia. Zhejiang Qianjiang Biochemical Co., Ltd. was founded in 1970 and is based in Haining, China.

www.qianjiangbioch.com

2,021

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600796.SS

View More

Performance Overview: 600796.SS

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600796.SS
1.57%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

600796.SS
15.41%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

600796.SS
9.60%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

600796.SS
17.21%
SSE Composite Index (000001.SS)
19.00%

Compare To: 600796.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600796.SS

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    4.90B

  • Enterprise Value

    6.50B

  • Trailing P/E

    29.74

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.68

  • Price/Book (mrq)

    1.48

  • Enterprise Value/Revenue

    3.67

  • Enterprise Value/EBITDA

    25.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.13%

  • Return on Assets (ttm)

    1.48%

  • Return on Equity (ttm)

    3.63%

  • Revenue (ttm)

    1.77B

  • Net Income Avi to Common (ttm)

    161.73M

  • Diluted EPS (ttm)

    0.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    820.9M

  • Total Debt/Equity (mrq)

    72.52%

  • Levered Free Cash Flow (ttm)

    -641.25M

Research Analysis: 600796.SS

View More

Company Insights: 600796.SS

Research Reports: 600796.SS

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.